All In Biotech

Drug Trial Radar · NCT02217410

CCFZ533X2201 - PoC Study in de Novo Renal Transplantation

A 12-month Randomized, Multiple Dose, Open-label, Study Evaluating Safety, Tolerability, Pharmacokinetics/Pharmacodynamics (PK/PD) and Efficacy of an Anti-CD40 Monoclonal Antibody, CFZ533, in Combination With Mycophenolate Mofetil (MMF) and Corticosteroids (CS), With and Without Tacrolimus (Tac), in de Novo Renal Transplant Recipients

Last checked: Nov 19, 2026Latest source record: Sep 28, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

59

Actual

Start

Feb 5, 2015

Primary completion

Nov 29, 2017

Study completion Nov 29, 2017

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Aug 15, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Basic science
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to investigate the safety, tolerability, pharmacokinetics (PK) and potential for CFZ533 to replace calcineurin inhibitors (CNI), while providing a similar rate of acute rejection prophylaxis and renal function in a de novo renal transplant population receiving an allograft from standard criteria donors.

Conditions

  • Kidney Transplantation

Interventions

  • CFZ533Biological

  • Tacrolimus (Tac)Drug

  • Mycophenolate mofetil (MMF)Drug

  • Corticosteroids (CS)Drug

  • anti-IL2 InductionBiological

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Cmax Pharmacokinetic Parameter- Part ITime frame: Day 1
  2. Mean Tmax Pharmacokinetic Parameter - Part ITime frame: Day 1
  3. Mean AUClast Pharmacokinetic Parameter - Part ITime frame: Day 1
  4. Efficacy as Defined by the Frequency and Severity (Banff Classification) of Treated Biopsy Proven Acute Rejection (tBPAR) Adjudicated Data - Part IITime frame: 3, 6, 9, and 12 months

Locations

14 sites in 4 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Aurora, Colorado

  • Novartis Investigative Site

    Baltimore, Maryland

  • Novartis Investigative Site

    Ann Arbor, Michigan

  • Novartis Investigative Site

    Detroit, Michigan

  • Novartis Investigative Site

    Livingston, New Jersey

  • Novartis Investigative Site

    Cincinnati, Ohio

  • Novartis Investigative Site

    São Paulo, São Paulo, Brazil

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Essen, Germany

  • Novartis Investigative Site

    Hamburg, Germany

  • Novartis Investigative Site

    Heidelberg, Germany

  • Novartis Investigative Site

    Groningen, Netherlands

  • Novartis Investigative Site

    Rotterdam, Netherlands

  • Novartis Investigative Site

    Utrecht, The Netherlands, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.